Neuromyelitis Optica Spectrum Disorder - 4 Studies Found
| NOT_YET_RECRUITING |
: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA� During Pregnancy : : 2025-07-30 : Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed.No study drug will be administered. |
| NOT_YET_RECRUITING |
: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders : : 2025-07-30 : Inebilizumab: 300mg IV on Day1 and Day 15.The first dose of inelizumab is given during IVMP. |
| COMPLETED |
: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) : Neuromyelitis Optica Spectrum Disorder : 2025-07-30 : IV, once every 12 weeks (Q12W) |
| COMPLETED |
: BLAZE-Limiting Approach in NMOSD : Neuromyelitis Optica Spectrum Disorders (NMOSD) : 2025-07-30 : Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks |